Coronado forms Mustang, pays City of Hope up to $40mm for CART IP; license expanded
Coronado Biosciences Inc. formed another division, Mustang Therapeutics Inc., which will develop IP in-licensed from the City of Hope focused on chimeric antigen receptor T-cell (CART) therapies for cancer.
- Gene Therapy, Cell Therapy
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.